Combining two targeted therapies for resistant EGFR-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced non-small cell lung cancer that cannot be surgically removed.
- Your cancer has a specific EGFR gene change (exon 19 deletion or L858R) that used to respond to EGFR-targeted drugs, but those drugs have stopped working.
- A recent biopsy or blood test shows an increased MET gene copy number (MET amplification).
- You have at least one tumor that can be measured with scans.
- You are generally well enough to carry out daily activities (ECOG 0-1) and have adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
This trial tests a combination of two targeted drugs (osimertinib and dalpiciclib) for people with advanced lung cancer whose tumors have a specific EGFR mutation and a change in the CDK4/6 pathway, and whose cancer has stopped responding to a third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.